PSTV raises $7.25M via private placement of shares and warrants

PLUS THERAPEUTICS, INC.

Gross proceeds of $7.25M from private placement of 3,591,532 units at $2.022/$2.158 per unit.
Units consist of one share (or pre-funded warrant) plus Series A and Series B warrants.
Series A warrants exercisable for 5 years, Series B warrants exercisable for 1 year after registration effectiveness.
Potential additional proceeds up to $12M from warrant exercises.
Insiders purchased $98,500 of securities.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PLUS THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain investors identified on the signature page thereto (collectively, the "Purchasers") valued at approximately $6.5 million (effective 2024-05-05).

Action: entry
Agreement: equity purchase
Counterparty: certain investors identified on the signature page thereto (collectively, the "Purchasers")
Value: approximately $6.5 million
Effective: 2024-05-05

Exact text from the filing

On May 5, 2024, Plus Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors identified on the signature page thereto (collectively, the “Purchasers”) for a private placement of securities (the “Initial Subscription”) for gross proceeds at the Closing Date (as defined below) of approximately $6.5 million.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PLUS THERAPEUTICS, INC. amended Securities Purchase Agreement with certain investors identified on the signature page thereto (collectively, the "Purchasers") valued at approximately $0.75 million (effective 2024-05-08).

Action: amendment
Agreement: equity purchase
Counterparty: certain investors identified on the signature page thereto (collectively, the "Purchasers")
Value: approximately $0.75 million
Effective: 2024-05-08

Exact text from the filing

On May 8, 2024, the Company entered into an amendment to the Securities Purchase Agreement (the “Amendment”) that increased the aggregate subscription amount by approximately $0.75 million (the “Additional Subscription”) for aggregate initial gross proceeds of approximately $7.25 million.

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-135399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.